Prostamol Uno in tratamentul pacienţilor cu hiperplazie benignă de prostată (experienţa de 10 ani)

Ceban Emil; Tănase Adrian; Lupaşco Constantin; Galescu Andrei; Botnari Vasile; Rusanovschii V.; Gorbatovschi Victor

Conţinutul numărului revistei

Articolul precedent

Articolul urmator

263

Ultima descărcare din IBN:
2023-07-16 11:15

SM ISO690:2012

CEBAN, Emil, TĂNASE, Adrian, LUPAŞCO, Constantin, GALESCU, Andrei, BOTNARI, Vasile, RUSANOVSCHII, V., GORBATOVSCHI, Victor. Prostamol Uno in tratamentul pacienţilor cu hiperplazie benignă de prostată (experienţa de 10 ani). In: Arta Medica , 2011, nr. 2S(45), pp. 35-38. ISSN 1810-1852.

EXPORT metadate:
Google Scholar
Crossref
CERIF

DataCite
Dublin Core

Arta Medica

Numărul 2S(45) / 2011 / ISSN 1810-1852 /ISSNe 1810-1879

Prostamol Uno in tratamentul pacienţilor cu hiperplazie benignă de prostată (experienţa de 10 ani)

Prostamol Uno in treatment of the patients with benign prostatic hyperplasia (experience of 10 years)

Pag. 35-38

Ceban Emil¹, Tănase Adrian¹, Lupaşco Constantin², Galescu Andrei¹, Botnari Vasile¹, Rusanovschii V.³, Gorbatovschi Victor²

¹ Universitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu“,
² IMSP Spitalul Clinic Republican „Timofei Moșneaga”,
³ IMSP Spitalul Raional, Edineţ

Disponibil în IBN: 25 martie 2022

Descarcă PDF

Rezumat

During 10 years, between 2001-2011, 760 patients with BPH were treated with Prostamol®Uno, 320mg, daily. In this trial patients were assessed pre- and post- treatment with International Prostate Symptom Score (IPSS), the Quality of Life (QOL), values of PSA and volume of residual urine appreciated ecographically. The analysis of our data shows decrease in IPSS score, QOL and volume of residual urine with in 53,4 %, 57,5% and 48,7% respectively. Prostamol®Uno is one of election drug in conservative treatment of BPH.